Iovance Biotherapeutics short interest was 32.69% of the float on April 15th, according to new data we received from Benzinga. Short interest totaled 108,804,045 shares, which was a decrease of -1.83% from March 31st.
It is estimated that it would take 6.54 days for short sellers to buy back their shares, with current trading volumes.
Iovance Biotherapeutics Hedge Fund Activity
We have seen 157 institutional investors add shares of Iovance Biotherapeutics stock to their portfolio, and 105 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BANK OF AMERICA CORP /DE/ added 7,998,583 shares (+127.4%) to their portfolio in Q4 2025, for an estimated $21,836,131
- STATE STREET CORP added 6,851,486 shares (+51.5%) to their portfolio in Q4 2025, for an estimated $18,704,556
- HRT FINANCIAL LP added 3,986,314 shares (+1078.3%) to their portfolio in Q4 2025, for an estimated $10,882,637
- D. E. SHAW & CO., INC. added 3,753,586 shares (+4925.4%) to their portfolio in Q4 2025, for an estimated $10,247,289
- MORGAN STANLEY added 3,610,277 shares (+64.7%) to their portfolio in Q4 2025, for an estimated $9,856,056
- BLACKROCK, INC. added 3,561,836 shares (+13.7%) to their portfolio in Q4 2025, for an estimated $9,723,812
- VANGUARD GROUP INC added 3,148,096 shares (+13.1%) to their portfolio in Q4 2025, for an estimated $8,594,302
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API.
Iovance Biotherapeutics Analyst Ratings
Wall Street analysts have issued reports on $IOVA in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Barclays issued a "Overweight" rating on 11/24/2025
To track analyst ratings and price targets for Iovance Biotherapeutics, check out Quiver Quantitative's $IOVA forecast page.
Iovance Biotherapeutics Price Targets
Multiple analysts have issued price targets for $IOVA recently. We have seen 4 analysts offer price targets for $IOVA in the last 6 months, with a median target of $8.0.
Here are some recent targets:
- Geulah Livshits from Chardan Capital set a target price of $16.0 on 04/10/2026
- David Dai from UBS set a target price of $4.0 on 03/05/2026
- Reni J. Benjamin from Citizens set a target price of $5.0 on 03/03/2026
- Etzer Darout from Barclays set a target price of $11.0 on 02/25/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
Check out the Quiver Quantitative API to build on top of data on congressional stock trading, insider transactions, hedge fund moves, and more.
